A phase 3 trial found that a personalized melanoma vaccine can improve patient outcomes. Johns Hopkins researchers helped test the approach in Baltimore and other centers.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Cancer vaccines show promise for treatment and prevention

Johns Hopkins Kimmel Cancer center
Personalized Melanoma Vaccine type
Phase 3 trial phase
More Than 30 Years research effort